Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Samra Turajlic

Showing results (21-30 of 126) with videos related to

Pageof 13
Sort By:
Therapeutic Advances in Medical Oncology|March 2, 2013
Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigmMuhammad Khattak, Rosalie Fisher, Samra Turajlic, et al.
Cancer Research|April 27, 2022
The Genetic Evolution of MetastasisAljosja Rogiers, Irene Lobon, Lavinia Spain, et al.
Nature Reviews. Genetics|March 29, 2019
Resolving genetic heterogeneity in cancerSamra Turajlic, Andrea Sottoriva, Trevor Graham, et al.
Expert Opinion on Investigational Drugs|May 7, 2013
Phase I/II RAF kinase inhibitors in cancer therapySamra Turajlic, Zohra Ali, Nadia Yousaf, et al.
Nature Cancer|June 28, 2022
The status of tumor mutational burden and immunotherapyValsamo Anagnostou, Alberto Bardelli, Timothy A Chan, et al.
European Journal of Cancer (Oxford, England : 1990)|January 28, 2023
The road to systemic therapy in von Hippel-Lindau (VHL) disease: Are we there yet?Scott T C Shepherd, William M Drake, Samra Turajlic
Current Opinion in Urology|July 1, 2015
How should clinicians address intratumour heterogeneity in clear cell renal cell carcinoma?Aspasia Soultati, Mark Stares, Charles Swanton, et al.
The Lancet. Oncology|August 8, 2015
Relapse models for clear cell renal carcinomaSakshi Gulati, Samra Turajlic, James Larkin, et al.
Journal for Immunotherapy of Cancer|July 17, 2021
Clinical and immunologic implications of COVID-19 in patients with melanoma and renal cell carcinoma receiving immune checkpoint inhibitorsBenjamin Switzer, John Haanen, Paul C Lorigan, et al.
ESMO Open|August 20, 2019
How we treat neurological toxicity from immune checkpoint inhibitorsLavinia Spain, Zayd Tippu, James M Larkin, et al.
Pageof 13

Showing results (21-30 of 126) with videos related to

Sort By:
Pageof 13
Therapeutic Advances in Medical Oncology|March 2, 2013
Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigmMuhammad Khattak, Rosalie Fisher, Samra Turajlic, et al.
Cancer Research|April 27, 2022
The Genetic Evolution of MetastasisAljosja Rogiers, Irene Lobon, Lavinia Spain, et al.
Nature Reviews. Genetics|March 29, 2019
Resolving genetic heterogeneity in cancerSamra Turajlic, Andrea Sottoriva, Trevor Graham, et al.
Expert Opinion on Investigational Drugs|May 7, 2013
Phase I/II RAF kinase inhibitors in cancer therapySamra Turajlic, Zohra Ali, Nadia Yousaf, et al.
Nature Cancer|June 28, 2022
The status of tumor mutational burden and immunotherapyValsamo Anagnostou, Alberto Bardelli, Timothy A Chan, et al.
European Journal of Cancer (Oxford, England : 1990)|January 28, 2023
The road to systemic therapy in von Hippel-Lindau (VHL) disease: Are we there yet?Scott T C Shepherd, William M Drake, Samra Turajlic
Current Opinion in Urology|July 1, 2015
How should clinicians address intratumour heterogeneity in clear cell renal cell carcinoma?Aspasia Soultati, Mark Stares, Charles Swanton, et al.
The Lancet. Oncology|August 8, 2015
Relapse models for clear cell renal carcinomaSakshi Gulati, Samra Turajlic, James Larkin, et al.
Journal for Immunotherapy of Cancer|July 17, 2021
Clinical and immunologic implications of COVID-19 in patients with melanoma and renal cell carcinoma receiving immune checkpoint inhibitorsBenjamin Switzer, John Haanen, Paul C Lorigan, et al.
ESMO Open|August 20, 2019
How we treat neurological toxicity from immune checkpoint inhibitorsLavinia Spain, Zayd Tippu, James M Larkin, et al.
Pageof 13